US 12,239,640 B2
Use of miloxacin in preparation of medicines for treating and/or preventing diseases with T-type calcium channels as therapeutic target
Jin Tao, Suzhou (CN); Yuan Zhang, Suzhou (CN); Yufang Sun, Suzhou (CN); and Xinghong Jiang, Suzhou (CN)
Assigned to SOOCHOW UNIVERSITY, Suzhou (CN)
Appl. No. 17/430,655
Filed by SOOCHOW UNIVERSITY, Suzhou (CN)
PCT Filed Feb. 20, 2021, PCT No. PCT/CN2021/077075
§ 371(c)(1), (2) Date Aug. 12, 2021,
PCT Pub. No. WO2022/077823, PCT Pub. Date Apr. 21, 2022.
Claims priority of application No. 202011092544.7 (CN), filed on Oct. 13, 2020.
Prior Publication US 2022/0305002 A1, Sep. 29, 2022
Int. Cl. A61K 31/4741 (2006.01); A61P 9/06 (2006.01); A61P 25/00 (2006.01); A61P 25/04 (2006.01); A61P 25/08 (2006.01); A61P 29/00 (2006.01); A61P 35/00 (2006.01)
CPC A61K 31/4741 (2013.01) [A61P 9/06 (2018.01); A61P 25/00 (2018.01); A61P 25/04 (2018.01); A61P 25/08 (2018.01); A61P 29/00 (2018.01); A61P 35/00 (2018.01)] 10 Claims
 
1. A method for treating a disease with T-type calcium channels as a therapeutic target, comprising:
preparing a medicine using miloxacin; and
treating a subject in need thereof with the medicine,
wherein the miloxacin is directly administrated.